Support Line: 0300 373 8500
Some people with non-Hodgkin Lymphoma have a protein called CD20 on their B-cells. This study is focussed on a type of treatment that targets this protein, giving researchers insight into what the right dosage is, and looking at different ways of giving the drug.
This study is on-going but currently closed to recruitment.
• Confirmed WM diagnosis; and are documented as having the the CD20 protein
• Previously been treated with a minimum of 2 lines of systemic therapy including at least one line with an anti-CD20 treatment
• No further standard treatment options remaining
